NEPH Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of 7.07% compared to Nephros, Inc.'s net margin of -12425.36%. Nephros, Inc.'s return on equity of 16.22% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Nephros, Inc. has a consensus price target of $6.50, signalling upside risk potential of 31.85%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 327.35%. Given that Perspective Therapeutics, Inc. has higher upside potential than Nephros, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Nephros, Inc..

Nephros, Inc. has a beta of 1.483, which suggesting that the stock is 48.288% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Nephros, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nephros, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Nephros, Inc. quarterly revenues are $4.8M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Nephros, Inc.'s net income of $337K is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Nephros, Inc.'s price-to-earnings ratio is 35.70x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nephros, Inc. is 2.96x versus 195.28x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Owlet, Inc. has a net margin of 7.07% compared to Nephros, Inc.'s net margin of 12.58%. Nephros, Inc.'s return on equity of 16.22% beat Owlet, Inc.'s return on equity of --.

Nephros, Inc. has a consensus price target of $6.50, signalling upside risk potential of 31.85%. On the other hand Owlet, Inc. has an analysts' consensus of $14.88 which suggests that it could fall by -4.22%. Given that Nephros, Inc. has higher upside potential than Owlet, Inc., analysts believe Nephros, Inc. is more attractive than Owlet, Inc..

Nephros, Inc. has a beta of 1.483, which suggesting that the stock is 48.288% more volatile than S&P 500. In comparison Owlet, Inc. has a beta of 1.734, suggesting its more volatile than the S&P 500 by 73.364%.

Nephros, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Owlet, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nephros, Inc. pays -- of its earnings as a dividend. Owlet, Inc. pays out -- of its earnings as a dividend.

Nephros, Inc. quarterly revenues are $4.8M, which are smaller than Owlet, Inc. quarterly revenues of $32M. Nephros, Inc.'s net income of $337K is lower than Owlet, Inc.'s net income of $4M. Notably, Nephros, Inc.'s price-to-earnings ratio is 35.70x while Owlet, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nephros, Inc. is 2.96x versus 2.60x for Owlet, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of 7.07% compared to Nephros, Inc.'s net margin of -862.39%. Nephros, Inc.'s return on equity of 16.22% beat VolitionRX Ltd.'s return on equity of --.

Nephros, Inc. has a consensus price target of $6.50, signalling upside risk potential of 31.85%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 780%. Given that VolitionRX Ltd. has higher upside potential than Nephros, Inc., analysts believe VolitionRX Ltd. is more attractive than Nephros, Inc..

Nephros, Inc. has a beta of 1.483, which suggesting that the stock is 48.288% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Nephros, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nephros, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Nephros, Inc. quarterly revenues are $4.8M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Nephros, Inc.'s net income of $337K is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Nephros, Inc.'s price-to-earnings ratio is 35.70x while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nephros, Inc. is 2.96x versus 17.13x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of 7.07% compared to Nephros, Inc.'s net margin of 3.93%. Nephros, Inc.'s return on equity of 16.22% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Nephros, Inc. has a consensus price target of $6.50, signalling upside risk potential of 31.85%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 93.3%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Nephros, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Nephros, Inc..

Nephros, Inc. has a beta of 1.483, which suggesting that the stock is 48.288% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Nephros, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nephros, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Nephros, Inc. quarterly revenues are $4.8M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Nephros, Inc.'s net income of $337K is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Nephros, Inc.'s price-to-earnings ratio is 35.70x while Xtant Medical Holdings, Inc.'s PE ratio is 76.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nephros, Inc. is 2.96x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.